Fludarabine
T-Cell And NK-Cell Neoplasm
Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02722668CT.gov UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | — | Completed | — | — | — |
NCT02287311CT.gov Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | — | Active Not Recruiting | — | — | — |
NCT00412360CT.gov Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell And NK-Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Masonic Cancer Center, University of Minnesota | P3 | BB · 68 |
| Cyclophosphamide | New York Medical College | P3 | BBB |
| Cyclosporin A | Medical College of Wisconsin | P3 | B |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | B |
| Equine Atg | Masonic Cancer Center, University of Minnesota | P2 | B |
| Umbilical Cord Blood Mononuclear Cells | Masonic Cancer Center, University of Minnesota | P2 | B |
| Lenalidomide | National Cancer Institute (NCI) | P1 | CCC |
| Pembrolizumab | The University of Hong Kong | P2 | CCC |
| Dexasone | National Cancer Institute (NCI) | P1 | CCC |
+18 more in the T-Cell And NK-Cell Neoplasm cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Fludarabine in T-Cell And NK-Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/fludarabine-t-cell-and-nk-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →